Skip to main content
All lobbying filings

DLA PIPER LLP (US)

Lobbying for BIOGEN, INC. · Biotechnology company.

 Filing 1st Quarter - Report
1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · House · Senate · $60,000.00 income · posted Apr 20, 2026

Official filing document

 Lobbying activity 6
Pharmacy

Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies.

Taxation/Internal Revenue Code

Issues related to tax reform.

Trade (domestic/foreign)

Trade-related public policy around tariffs and intellectual property.

Health Issues

Issues related to rare diseases including Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Lou Gehrig's Disease. Drug pricing and drug development policies. Screening and diagnosis. Patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues. Orphan Drug Act. Issues related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials. Policies related to value based arrangements.

Medical/Disease Research/Clinical Labs

Issues related to rare disease and treatment. Drug pricing policy. Issues related to the Medicaid 340B program. Public policy around patients' access and affordability. Alzheimer's disease. Issues related to Medicare Part B and D.

Copyright/Patent/Trademark

Intellectual property protections and enforcement. Biopharmaceutical patent policy.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem